Project Grant R35GM161245
- Federal Grant Award Summary The University of California, Davis received a $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025 through July 31, 2027. This award funds fundamental research investigating the role of mismatch repair proteins MSH2 and MSH6 in maintaining genome stability and preventing erroneous homologous recombination. The research employs...
- Federal Grant Award Summary The University of California, Davis received a $435,405 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 11, 2026, with completion scheduled for January 31, 2031. This Maximizing Investigators' Research Award (MIRA) R35 supports a five-year research program investigating the causes and consequences of genome instability and chromosome rearrangements...
- Federal Project Grant Award Summary The University of California, Davis received a $393,008 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through December 31, 2030. This award funds fundamental basic research investigating the molecular mechanisms that regulate cell fate specification during the complete regeneration of complex sensory organs. The project leverages...
- Federal Project Grant Award Summary The University of California, Davis received a $435,769 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2030. This award funds research to advance understanding of the physical biology of the cellular glycocalyx—the sugar- and protein-rich material covering all cells. The project will develop specialized...
- Federal Grant Award Summary The University of California, San Diego received a Project Grant award of $376,498 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, with a completion date of July 31, 2030. The award funds research into active genetic systems—CRISPR-based genetic technologies that bypass traditional inheritance patterns to enable self-propagating genetic elements known...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded a Project Grant totaling $616,786 to The Regents of the University of California, San Francisco (UCSF) under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2025 through May 31, 2030. This five-year award supports fundamental research investigating how evolutionary forces shape genetic variation and phenotypic diversity across human populations. The...
- Federal Grant Award Summary The University of California, Davis received a $402,051 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective February 26, 2026, with a completion date of December 31, 2030. This award funds a comprehensive research initiative focused on multi-glycomic characterization of cell membranes and the role of glycans in protein-protein interactions. The...
- Federal Project Grant Award Summary The University of California, San Francisco received a $410,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025 through June 30, 2030. The award supports development of novel computational and analytical approaches to reconstruct heterogeneous infectious disease transmission dynamics from pathogen genomic sequence data. The...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $420,984 Project Grant to the University of California, Los Angeles (UCLA) effective August 1, 2025, with a completion date of July 31, 2030. This award supports the development of statistical methods and analytical approaches to interpret deep mutational scanning (DMS) data, a high-throughput technology used to...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Los Angeles $363,570 on March 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop integrated computational and analytical methods for reconstructing three-dimensional (3D) genome structures from single cells. The project, which runs through February 28, 2030, addresses critical limitations in current genome structure models by...
The University of California, Davis received a $391,526 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026, through December 31, 2030. This award supports the development of computational methods to elucidate the contributions of structural variants (SVs)—genetic rearrangements greater than 50 base pairs—to complex diseases, including neurodevelopmental disorders and cancers. The research addresses critical gaps in current genomic analysis by focusing on SVs in repetitive and hard-to-call regions of the genome, which comprise approximately 15% of the genome but remain poorly characterized by existing sequencing and analysis tools. The project will deliver computational tools and methodologies to accurately predict, genotype, and interpret de novo and somatic SVs in complex genomic regions that have been largely overlooked in large-scale disease studies. By advancing the technical capability to detect and analyze SVs in repetitive regions of the genome, this research will enable comprehensive investigation of SV contributions to complex disorders and establish the scientific foundation for improved disease diagnosis and understanding of genetic mechanisms underlying neurodevelopmental and malignant diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $391.5k | 5/1/26 |